Paul, Weiss, Rifkind, Wharton & Garrison has added Ian Edvalson as a partner in its Corporate Department in San Francisco, strengthening the firm’s life sciences transactions and intellectual property capabilities. Edvalson focuses on transactions involving public and private biopharmaceutical, medical technology and other life sciences companies.
His practice covers licensing and collaboration agreements, intellectual property matters related to mergers and acquisitions, and other commercial arrangements supporting the development and commercialization of life sciences products and services.
The addition is intended to bolster Paul, Weiss’ ability to advise life sciences companies on complex strategic transactions where intellectual property, technology and commercialization rights are central to the deal.
Edvalson joins Paul, Weiss from Wilson Sonsini.
His work spans the full lifecycle of life sciences transactions, including agreements governing the development, licensing and commercialization of pharmaceutical and biotechnology assets.
Paul, Weiss said Edvalson’s experience will complement its Intellectual Property & Technology Transactions Practice, which works alongside the firm’s corporate teams on transactions involving patents, technology and other intangible assets.
The practice advises clients on how intellectual property assets fit within broader deal structures and develops transactional strategies designed to identify opportunities and address IP-related risks.
Edvalson has been recognized by Chambers USA in the Life Sciences: Corporate/Commercial – California category since 2021 and was also recognized from 2007 through 2014.
He earned a bachelor’s degree in Korean and a Bachelor of Science in Molecular Biology from Brigham Young University and received his law degree from the University of Chicago Law School.
Paul, Weiss has more than 1,500 lawyers globally and advises corporations, financial institutions and asset managers across corporate transactions, litigation and restructuring matters.
KEY QUOTES:
“Ian’s work across the entire spectrum of life sciences transactions will be incredibly valuable to our clients as we continue to support them on their most complex deals and commercial agreements in the sector. We are thrilled to welcome him to the firm.”
Angelo Bonvino, Global Head of the Paul, Weiss Corporate Department
“Ian brings a stellar track record of providing the sophisticated counsel that life sciences companies need to execute pivotal transactions, including licensing and collaboration agreements.”
“He is a terrific lawyer whose commercial and strategic approach will strengthen our growing IP practice.”
Jeffrey Osterman, Global Co-Head of Intellectual Property & Technology Transactions and Chair of Life Sciences Licensing & Collaboration Transactions at Paul, Weiss
